---
title: "Goldman Sachs: The mainland medical sector will rely more on data and profit visibility this year, optimistic about CDMO companies"
description: "Goldman Sachs report indicates that the mainland healthcare sector will continue to be strong, but investors need to pay attention to the value of the R&D pipeline. Outperformance depends on key data "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275091417.md"
published_at: "2026-02-06T07:18:07.000Z"
---

# Goldman Sachs: The mainland medical sector will rely more on data and profit visibility this year, optimistic about CDMO companies

> Goldman Sachs report indicates that the mainland healthcare sector will continue to be strong, but investors need to pay attention to the value of the R&D pipeline. Outperformance depends on key data and earnings visibility. Positive on CDMO companies, upgrading WuXi AppTec and WUXI XDC ratings to "Buy." A selective strategy is recommended for biotech and pharmaceutical companies, recommending SKB BIO-B, HENLIUS, and HANSOH PHARMA. The medical device sector maintains a neutral stance, recommending ANGELALIGN and WEIGAO GROUP. A cautious attitude is taken towards the medical services sector, downgrading HYGEIA HEALTH and JXR ratings

Goldman Sachs' research report indicates that the strong trend in the mainland healthcare sector last year will continue into this year. However, investors are considering more of the value of R&D pipelines when assessing valuations, leading to stock trading being more based on the actual execution capabilities of companies rather than merely expectations of licensing deals. This year, achieving returns that exceed the industry will rely more on the release of key data, actual transactions, and visibility on profit realization or turning points.

In terms of specific segments, the bank has become more constructive on CDMO companies, based on their accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations; it has upgraded WuXi AppTec (02359.HK)(603259.SH) and WUXI XDC (02268.HK) to "Buy."

As for biotechnology and pharmaceutical companies, the bank has adopted a selective strategy, favoring companies with key data releases and early data showing some prospects, along with expectations of actual transactions; it is optimistic about SKB BIO (06990.HK), HENLIUS (02696.HK), and HANSOH PHARMA (03692.HK).

The bank maintains a neutral view on the medical device sector, noting that while the industry has bottomed out, it will take time to gradually recover; it recommends buying ANGELALIGN (06699.HK) and WEIGAO GROUP (01066.HK). In the medical services sector, the bank remains relatively cautious due to the ongoing impact of cost control measures and a weak consumer cycle; it has downgraded HYGEIA HEALTH (06078.HK) and JXR (01951.HK) ratings to "Neutral" and "Sell," respectively

### Related Stocks

- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)
- [512290.CN - Guotai CSI Bio-medicine ETF](https://longbridge.com/en/quote/512290.CN.md)
- [159570.CN - China Universal CNI HK Connect Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159570.CN.md)
- [03692.HK - HANSOH PHARMA](https://longbridge.com/en/quote/03692.HK.md)
- [510660.CN - ChinaAMC SSE Health Care ETF Initiating Fund](https://longbridge.com/en/quote/510660.CN.md)
- [513700.CN - Penghua CSI HK Connect Health Care Composite ETF](https://longbridge.com/en/quote/513700.CN.md)
- [06990.HK - SKB BIO-B](https://longbridge.com/en/quote/06990.HK.md)
- [588130.CN - ChinaAMC SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588130.CN.md)
- [002422.CN - KELUN PHARMA](https://longbridge.com/en/quote/002422.CN.md)
- [02696.HK - HENLIUS](https://longbridge.com/en/quote/02696.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 顶尖卓越医疗以 1.003 亿港元收购在线医疗平台的关联交易 | 顶尖卓越医疗集团有限公司将以 1 亿港元收购顶尖卓越二有限公司 100% 的股份，此交易属于香港上市规则下的关联交易。此次收购使顶尖卓越能够整合来自中国大陆互联网医疗实体的财务业绩。由于卖方是控股股东的子公司，因此需要独立股东的批准。已成立 | [Link](https://longbridge.com/en/news/277135842.md) |
| 百济神州公布了 2025 年的业绩，并对 2026 年的展望持谨慎态度 | 百济神州有限公司是一家总部位于瑞士并在香港上市的生物制药公司，已发布 2025 年第四季度未经审计的合并财务结果和全年审计结果。该公司对 2026 年提供了谨慎的财务展望，强调该指导意见为初步，可能因临床和监管风险而有所变化。最新的分析师评 | [Link](https://longbridge.com/en/news/277035413.md) |
| Nuvia Dental Implant Center 被 BizTech Outlook 评选为 2026 年十大值得关注的公司之一 | Nuvia Dental Implant Center 被 BizTech Outlook 评选为 “2026 年十大值得关注公司” 之一，因其在全口牙种植方面的创新方法。该中心强调速度、安全和以患者为中心的护理，使患者在手术后仅需 24  | [Link](https://longbridge.com/en/news/277089366.md) |
| 百济神州 Q4 营收同比增长 33%，全年扭亏为盈，百悦泽单季狂揽 11 亿创历史新高｜财报见闻 | 百济神州 2025 年全年营收 53.43 亿美元，同比增长 40%。旗舰药百悦泽全球销售额达 39 亿美元，稳居赛道第一。公司经营现金流与净利润双双转正，彻底告别 “烧钱” 模式。展望 2026 年，随新药临近商业化，总收入指引上调至 6 | [Link](https://longbridge.com/en/news/277044073.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.